Plasma YKL-40 as a Biomarker for Bevacizumab Efficacy in Patients With Newly Diagnosed Glioblastoma in the Phase 3 Randomized AVAglio Trial
Oncotarget - United States
doi 10.18632/oncotarget.22886
Full Text
Open PDFAbstract
Available in full text
Categories
Date
December 4, 2017
Authors
Publisher
Impact Journals, LLC